Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z2CN
|
||||
| Former ID |
DNC007573
|
||||
| Drug Name |
ISOGRANULATIMIDE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H8N4O2
|
||||
| InChI |
InChI=1S/C15H8N4O2/c20-14-11-9-5-16-6-19(9)13-10(12(11)15(21)18-14)7-3-1-2-4-8(7)17-13/h1-6,17H,(H,18,20,21)
|
||||
| InChIKey |
WXUJAQBSBZLVEV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Serine/threonine-protein kinase Chk1 | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell cycle | ||||
| p53 signaling pathway | |||||
| HTLV-I infection | |||||
| Viral carcinogenesis | |||||
| Pathway Interaction Database | Fanconi anemia pathway | ||||
| p73 transcription factor network | |||||
| ATR signaling pathway | |||||
| Circadian rhythm pathway | |||||
| p53 pathway | |||||
| Reactome | Activation of ATR in response to replication stress | ||||
| Processing of DNA double-strand break ends | |||||
| Presynaptic phase of homologous DNA pairing and strand exchange | |||||
| G2/M DNA damage checkpoint | |||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |||||
| WikiPathways | DNA Damage Response | ||||
| Signaling by SCF-KIT | |||||
| ATM Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Cell Cycle | |||||
| Cell Cycle Checkpoints | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5991). | ||||
| REF 2 | Eur J Med Chem. 2008 Feb;43(2):282-92. Epub 2007 Apr 7.Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c]carbazole-1,3,4,7-tetraone. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.